Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
CRDF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.90 - $5.64
Previous CloseN/A
Volume446.20K
Average Volume (3M)1.06M
Market Cap
$137.71M
Enterprise Value$139.78M
Total Cash (Recent Filing)$70.96M
Total Debt (Recent Filing)$1.19M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Oct 30, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding66,525,856
10 Day Avg. Volume726,990
30 Day Avg. Volume1,060,504
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue256.02
Enterprise Value/Gross Profit310.63
Enterprise Value/Ebitda-2.59
Forecast
1Y Price Target
$14.50Price Target Upside600.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical DataThe data suggests onvansertib is clearly active and exhibits an additive effect to the standard of care in metastatic colorectal cancer.
Financial ResourcesCardiff's financial resources are considered sufficient to provide an operational runway into 1Q27.
Bears Say
Risk FactorsRisks include negative clinical results, delays, failure to obtain approval, lower market penetration rates, and potential dilution risk.
Trial TimingThe ongoing Phase II CRDF-004 trial will now read out later than initially expected, which might concern investors.
Cardiff Oncology News
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $1.90 and its highest was $5.64 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $137.71M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Oct 30, 2025 which is in 34 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Jul 29, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.192 by -$0.018.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.21.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 66,525,856 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.192. Following the earnings report the stock price went down -24.773%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (600.48% Upside)
$14.50 (600.48% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 134.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $710.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.93%
12-Months-Change
Fundamentals
Return on Equity
-91.93%
Trailing 12-Months
Asset Growth
14.67%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
CRDF Stock 12 Month Forecast
Average Price Target
$14.50
▲(600.48% Upside)
Technical Analysis
Neurogene
―
Annexon Biosciences
―
Innate Pharma
―
Design Therapeutics
―
Third Harmonic Bio, Inc.
―
Ownership Overview
4.43% Insiders
7.84% Mutual Funds
13.47% Other Institutional Investors
65.44% Public Companies and Individual Investors